Sooma’s tDCS system is a portable, patient-administered neuromodulation device that uses a mild electrical current to stimulate the brain and alleviate the symptoms of depression. Image Credit: 13_Phunkod / Shutterstock.

Finland-based Sooma Medical has raised €5m ($5.5m) in venture funding to expand market access for its transcranial direct current stimulation (tDCS) device for at-home treatment of depression.

The financing round was led by Finnish Venture Capital firm, Voima Ventures. The company plans to use the funds to accelerate product development and expand into new and existing markets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The tDCS system is a portable, patient-administered neuromodulation device that uses a mild electrical current to stimulate the brain and alleviate the symptoms of depression. The device requires a physician’s prescription and can be used as either a stand-alone treatment or as an add-on therapy. The treatment includes a daily 30-minute session for a minimum of three weeks.

The device has been approved in the European Union (EU) and was granted a breakthrough device designation by the US Food and Drug Administration (FDA). The therapy is available in over 35 countries.

The global market for neuromodulation devices was worth approximately $6.6bn in 2022 and is expected to reach over $8.9bn in 2027, as per a GlobalData market analysis.

See Also:

Although being first developed for the treatment of depression, neuromodulation devices are being developed to treat a variety of neurological disorders. In October 2023, Neurovalens’ neurostimulation device, Modius Sleep, received 510(k) clearance from the US Food and Drug Administration (FDA) to treat chronic insomnia. In August 2023, Dutch startup Salvia BioElectronics treated the first patient using its implantable neurostimulation system for treatment of  severe migraine and cluster headaches.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In January, SpineX published positive results from a first-in-human study evaluating the use of its electrical neuromodulation device in a patient with cerebral palsy. After eight weeks of using SpineX’s Spinal Cord Innovation in Pediatrics (SCiP) therapy, the patient had a 14.2-point increase in gross motor function as measured by the Gross Motor Function Classification System (GMFM) score.

NeuroPace is also conducting a clinical trial to investigate its neuromodulation therapy for the treatment of idiopathic generalised epilepsy. In September 2023, PathMaker Neurosystems started an early feasibility study investigating its non-invasive neuromodulation device in patients with amyotrophic lateral sclerosis (ALS).